Company News
Greenwich LifeSciences Jump 7.7% After EMA Approval
Greenwich LifeSciences stock rose 7.7% after EMA cleared commercially manufactured GP2 for its FLAMINGO‑01 Phase III breast‑cancer trial.
EMA approval enables US and European sites (now ~170‑180) to u
